• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Frazier Healthcare Partners Announces Multiple Promotions on its Life Sciences Team

    1/7/21 8:00:00 AM ET
    $TRIL
    $PHAT
    $RCKT
    $PASG
    Major Pharmaceuticals
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TRIL alert in real time by email

    MENLO PARK, Calif.--(BUSINESS WIRE)--Frazier Healthcare Partners announced the promotion of several members on its Life Sciences team: Aditya Kohli to Venture Partner, Anna Chen to Vice President, and Max Nowicki to Senior Associate.

    Aditya Kohli, Ph.D., joined the Frazier Life Sciences team in 2016 and focuses on company creation. He co-founded Phathom Pharmaceuticals (NASDAQ: PHAT) and Scout Bio, and helped launch Passage Bio (NASDAQ: PASG). Dr. Kohli serves as the Chief Business Officer of Phathom Pharmaceuticals and as a member of the board of directors for Scout Bio.

    Anna Chen, Ph.D., joined Frazier in 2018 and focuses on evaluating investment opportunities and creating new ventures in the life sciences sector. She is a board observer for Amunix Pharmaceuticals and Inipharm.

    Max Nowicki, M.D., joined the Frazier Life Sciences team in 2019 and focuses on identifying new public and private investment opportunities. He has been involved in numerous Frazier investments, including Rocket Pharmaceuticals (NASDAQ: RCKT) and Trillium Therapeutics (NASDAQ: TRIL).

    “We are thrilled to announce the promotions of Aditya, Anna, and Max,” said James Topper, Managing Partner at Frazier. “They are extremely valuable members of our team, and are instrumental in helping us create new companies, as well as invest in new public and private companies.”

    About Frazier Healthcare Partners

    Founded in 1991, Frazier Healthcare Partners is a leading provider of growth and venture capital to healthcare companies. With nearly $4.8 billion total capital raised, Frazier has invested in over 200 companies, with investment types ranging from company creation and venture capital to buyouts of profitable lower-middle market companies. The firm’s Growth Buyout team invests in healthcare and pharmaceutical services, medical products and related sectors. The Life Sciences team invests in therapeutics and related areas that are addressing unmet medical needs through innovation. Frazier has offices in Seattle, WA and Menlo Park, CA, and invests broadly across the US, Canada, and Europe.

    For more information about Frazier Healthcare Partners, visit the company's website at http://www.frazierhealthcare.com.

    Get the next $TRIL alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TRIL
    $PHAT
    $RCKT
    $PASG

    CompanyDatePrice TargetRatingAnalyst
    Rocket Pharmaceuticals Inc.
    $RCKT
    8/20/2025$10.00Neutral → Buy
    BofA Securities
    Rocket Pharmaceuticals Inc.
    $RCKT
    7/25/2025$4.00Buy → Neutral
    BofA Securities
    Rocket Pharmaceuticals Inc.
    $RCKT
    5/30/2025$5.00Outperform → In-line
    Evercore ISI
    Rocket Pharmaceuticals Inc.
    $RCKT
    5/28/2025Overweight → Neutral
    Analyst
    Rocket Pharmaceuticals Inc.
    $RCKT
    5/28/2025$2.00Neutral → Sell
    Goldman
    Rocket Pharmaceuticals Inc.
    $RCKT
    5/28/2025$8.00Outperform → Market Perform
    Leerink Partners
    Rocket Pharmaceuticals Inc.
    $RCKT
    5/28/2025$2.50Buy → Hold
    Jefferies
    Rocket Pharmaceuticals Inc.
    $RCKT
    5/28/2025$7.00Overweight → Equal-Weight
    Morgan Stanley
    More analyst ratings

    $TRIL
    $PHAT
    $RCKT
    $PASG
    SEC Filings

    View All

    SEC Form 10-Q filed by Rocket Pharmaceuticals Inc.

    10-Q - ROCKET PHARMACEUTICALS, INC. (0001281895) (Filer)

    11/6/25 4:06:46 PM ET
    $RCKT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rocket Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - ROCKET PHARMACEUTICALS, INC. (0001281895) (Filer)

    11/6/25 4:04:18 PM ET
    $RCKT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Phathom Pharmaceuticals Inc.

    8-K - Phathom Pharmaceuticals, Inc. (0001783183) (Filer)

    11/4/25 7:05:25 AM ET
    $PHAT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TRIL
    $PHAT
    $RCKT
    $PASG
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Rocket Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Progress

    Pivotal Phase 2 trial of RP-A501 for Danon disease to resume in 1H 2026 KRESLADI™ for severe LAD-I on track for March 28, 2026 PDUFA date Leadership updates with the appointments of Dr. Syed Rizvi, Chief Medical Officer, Christopher Stevens, Chief Operating Officer, and Sarbani Chaudhuri, Chief Commercial & Medical Affairs Officer Cash, cash equivalents and investments of approximately $222.8M; expected operational runway into the second quarter of 2027 Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today reported financial and recent operation

    11/6/25 4:00:00 PM ET
    $RCKT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Passage Bio to Present at Guggenheim Securities 2nd Annual Healthcare Innovation Conference

    PHILADELPHIA, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ:PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that Will Chou, M.D., president and chief executive officer, will participate in a fireside chat during the Guggenheim Securities 2nd Annual Healthcare Innovation Conference on Wednesday, November 12, 2025 at 9:30 a.m. ET in Boston, MA. A live webcast of the event will be available on the Investors & News section of Passage Bio's website at investors.passagebio.com. A replay of the event will be available for 90 days following the event. About Passage Bio Passage Bio (NASDAQ

    11/5/25 7:00:00 AM ET
    $PASG
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Phathom Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)

    First patient dosed, with topline results expected in 2027pHalcon-EoE-201 is the first large, well-controlled clinical trial of an acid secretory treatment in EoE FLORHAM PARK, N.J., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced the first patient has been dosed in its Phase 2 pHalcon-EoE-201 clinical trial evaluating VOQUEZNA® (vonoprazan) tablets as an investigational treatment for eosinophilic esophagitis (EoE) in adults. "The initiation of the pHalcon-EoE-201 study reflects Phathom's commitment to advancing care for

    11/4/25 8:00:00 AM ET
    $PHAT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TRIL
    $PHAT
    $RCKT
    $PASG
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Lynx1 Capital Management Lp bought $2,261 worth of shares (325 units at $6.96) and bought $221,474 worth of shares (31,683 units at $6.99) (SEC Form 4)

    4 - Passage BIO, Inc. (0001787297) (Issuer)

    9/15/25 8:05:45 PM ET
    $PASG
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Bjork Elisabeth bought $34,100 worth of shares (10,000 units at $3.41), increasing direct ownership by 33% to 40,000 units (SEC Form 4)

    4 - ROCKET PHARMACEUTICALS, INC. (0001281895) (Issuer)

    8/27/25 8:54:13 PM ET
    $RCKT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Lynx1 Capital Management Lp bought $662,488 worth of shares (115,725 units at $5.72) and bought $71,338 worth of shares (13,123 units at $5.44) (SEC Form 4)

    4 - Passage BIO, Inc. (0001787297) (Issuer)

    7/24/25 6:12:54 PM ET
    $PASG
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TRIL
    $PHAT
    $RCKT
    $PASG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Principal Accounting Officer Breedlove Robert Charles sold $7,079 worth of shares (524 units at $13.51), decreasing direct ownership by 1% to 47,407 units (SEC Form 4)

    4 - Phathom Pharmaceuticals, Inc. (0001783183) (Issuer)

    11/5/25 4:30:03 PM ET
    $PHAT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Officer Militello John sold $114,581 worth of shares (28,918 units at $3.96), decreasing direct ownership by 30% to 67,006 units (SEC Form 4)

    4 - ROCKET PHARMACEUTICALS, INC. (0001281895) (Issuer)

    10/16/25 4:01:50 PM ET
    $RCKT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: Chief Financial & Bus. Officer Narula Sanjeev was granted 144,000 shares (SEC Form 4)

    4/A - Phathom Pharmaceuticals, Inc. (0001783183) (Issuer)

    10/8/25 5:09:21 PM ET
    $PHAT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TRIL
    $PHAT
    $RCKT
    $PASG
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for VOQUEZNA issued to PHATHOM PHARMACEUTICALS INC

    Submission status for PHATHOM PHARMACEUTICALS INC's drug VOQUEZNA (ORIG-1) with active ingredient VONOPRAZAN FUMARATE has changed to 'Approval' on 07/17/2024. Application Category: NDA, Application Number: 218710, Application Classification: Type 9 - New Indication Submitted as Distinct NDA, Consolidated with Original NDA after Approval

    7/18/24 10:52:01 AM ET
    $PHAT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for VOQUEZNA TRIPLE PAK issued to PHATHOM PHARMACEUTICALS, INC

    Submission status for PHATHOM PHARMACEUTICALS, INC's drug VOQUEZNA TRIPLE PAK (ORIG-1) with active ingredient AMOXICILLIN; CLARITHROMYCIN; VONOPRAZAN has changed to 'Approval' on 05/03/2022. Application Category: NDA, Application Number: 215152, Application Classification: Type 1 - New Molecular Entity and Type 4 - New Combination

    5/11/22 10:51:07 AM ET
    $PHAT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for VOQUEZNA DUAL PAK issued to PHATHOM PHARMACEUTICALS, INC

    Submission status for PHATHOM PHARMACEUTICALS, INC's drug VOQUEZNA DUAL PAK (ORIG-1) with active ingredient AMOXICILLIN; VONOPRAZAN has changed to 'Approval' on 05/03/2022. Application Category: NDA, Application Number: 215153, Application Classification: Type 5 - New Formulation or New Manufacturer

    5/11/22 10:17:03 AM ET
    $PHAT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TRIL
    $PHAT
    $RCKT
    $PASG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Rocket Pharmaceuticals upgraded by BofA Securities with a new price target

    BofA Securities upgraded Rocket Pharmaceuticals from Neutral to Buy and set a new price target of $10.00

    8/20/25 2:00:01 PM ET
    $RCKT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rocket Pharmaceuticals downgraded by BofA Securities with a new price target

    BofA Securities downgraded Rocket Pharmaceuticals from Buy to Neutral and set a new price target of $4.00

    7/25/25 9:00:02 AM ET
    $RCKT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rocket Pharmaceuticals downgraded by Evercore ISI with a new price target

    Evercore ISI downgraded Rocket Pharmaceuticals from Outperform to In-line and set a new price target of $5.00

    5/30/25 10:04:19 AM ET
    $RCKT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TRIL
    $PHAT
    $RCKT
    $PASG
    Financials

    Live finance-specific insights

    View All

    Phathom Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

    Over 790,000 total VOQUEZNA® prescriptions filled to dateFilled VOQUEZNA prescriptions increased 28% from Q2 2025Net revenues of $49.5 million, up 25% quarter over quarter, and cash operating expenses down 43% quarter over quarterFull-year 2025 revenue guidance updated to $170–$175 million; company expects to achieve operating profitability in 2026Management to host conference call today, October 30, 2025, at 8:00 a.m. ET FLORHAM PARK, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) --  Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today reported financial results for the third q

    10/30/25 7:00:00 AM ET
    $PHAT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Phathom Pharmaceuticals to Report Third Quarter 2025 Financial Results and Provide Business Update on Thursday, October 30, 2025

    Management to host conference call on Thursday, October 30, 2025, at 8:00 am EDT FLORHAM PARK, N.J., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that it will host a live webcast at 8:00 am EDT on Thursday, October 30, 2025, to report its third quarter 2025 financial results and provide a business update. A live webcast and additional information about the presentation can be accessed on the Events & Presentations section of the Phathom website at https://investors.phathompharma.com/news-events/events-and-presentations. A

    10/20/25 8:00:03 AM ET
    $PHAT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Phathom Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates

    Over 580,000 VOQUEZNA® prescriptions filled to date, reflecting 49% growth since last earnings reportNet revenues of $39.5 million reported for Q2Full-year 2025 revenue guidance of $165 million to $175 millionCompany remains focused on path to profitability in 2026Management to host conference call today, August 7, 2025, at 8:00 a.m. ET FLORHAM PARK, N.J., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today reported financial results for the second quarter ended June 30, 2025, and provided business updates. "The second quarter marked

    8/7/25 6:59:20 AM ET
    $PHAT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TRIL
    $PHAT
    $RCKT
    $PASG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Rocket Pharmaceuticals Inc.

    SC 13D/A - ROCKET PHARMACEUTICALS, INC. (0001281895) (Subject)

    12/16/24 7:51:51 PM ET
    $RCKT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Passage Bio Inc.

    SC 13G - Passage BIO, Inc. (0001787297) (Subject)

    11/14/24 12:03:11 PM ET
    $PASG
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Rocket Pharmaceuticals Inc.

    SC 13G/A - ROCKET PHARMACEUTICALS, INC. (0001281895) (Subject)

    11/8/24 10:52:38 AM ET
    $RCKT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TRIL
    $PHAT
    $RCKT
    $PASG
    Leadership Updates

    Live Leadership Updates

    View All

    Phathom Pharmaceuticals Appoints Sanjeev Narula as Chief Financial and Business Officer

    Sanjeev Narula brings proven success in scaling commercial-stage biopharma companies with expertise in capital and investor strategies, M&A, and operational excellenceAppointment strengthens Phathom's leadership team and ability to execute its growth strategy in GI FLORHAM PARK, N.J., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced the appointment of Sanjeev Narula as Chief Financial and Business Officer. "We welcome Sanjeev to Phathom's leadership team at this important stage of our growth," said Steve Basta, President

    10/6/25 8:00:00 AM ET
    $PHAT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    FLORHAM PARK, N.J., June 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced that, in connection with the appointment of Anne Marie Cook as Chief Legal Officer and Corporate Secretary, the Company's Board of Directors has approved the grant of inducement awards. On June 23, 2025, the Compensation Committee of the Company's Board of Directors granted inducement awards to Ms. Cook under the Company's 2025 Employment Inducement Incentive Award Plan (the "Inducement Plan"). Ms. Cook was granted a non-qualified stock option to purchase

    6/23/25 4:15:00 PM ET
    $PHAT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Phathom Pharmaceuticals Appoints Anne Marie Cook as Chief Legal Officer and Corporate Secretary

    FLORHAM PARK, N.J., June 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced the appointment of Anne Marie Cook, J.D., as Chief Legal Officer and Corporate Secretary. Ms. Cook is an accomplished pharmaceutical legal executive with a proven track record advising pharmaceutical companies and broad expertise in corporate governance, commercial law, regulatory compliance, strategic transactions and legal strategy. Ms. Cook most recently served as Senior Vice President, General Counsel of Sage Therapeutics, Inc. and previously se

    6/23/25 7:59:57 AM ET
    $PHAT
    $SAGE
    Biotechnology: Pharmaceutical Preparations
    Health Care